Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hypermethylated in cancer 1 (HIC1)
- Target
- HIC1
- Molecular classification
- Transcription factor, Zinc finger protein, BTB domain-containing protein
01
Overview
Hypermethylated in cancer 1 (HIC1), also known as HIC ZBTB transcriptional repressor 1, is a transcriptional repressor protein belonging to the ZBTB family, characterized by a BTB/POZ domain and C2H2-type zinc finger motifs[4][1][2][3]. HIC1 functions mainly as a tumor suppressor and growth regulator, frequently inactivated in cancer through promoter hypermethylation or chromosomal deletion[4][7]. Its transcriptional repression activity inhibits gene expression by binding to DNA and recruiting corepressors and histone-modifying enzymes via its BTB domain[1][2]. HIC1 is implicated in maintaining genomic integrity and regulating responses to DNA damage. Loss or silencing of HIC1 is recognized in the pathogenesis of multiple cancers, including breast, colorectal, and brain tumors[4]. It is not considered a direct therapeutic target (not a receptor, enzyme, or transporter), but its inactivation status is a relevant cancer biomarker.
- Other names
- Hypermethylated in cancer 1ZBTB transcriptional repressor 1HIC ZBTB transcriptional repressor 1ZBTB29
02
Biological functions
Transcriptional repressionTumor suppressionRegulation of cell growthMaintenance of genomic integrityNegative regulation of Wnt signaling pathway
03
Disease associations
Cancer (tumor suppressor in multiple cancers, including colorectal and breast)Other (associated with tumor progression via hypermethylation or deletion)
04
Biomarkers
Hypermethylation of HIC1 as a biomarker for various cancers[4]
Beyond the preview
Go deeper on Hypermethylated in cancer 1 (HIC1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hypermethylated in cancer 1 (HIC1).